about
A global approach to HIV-1 vaccine developmentImmunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaquesRecombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsDefining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.Vaccine design for CD8 T lymphocyte responsesControlling the HIV/AIDS epidemic: current status and global challengesHuman immunodeficiency virus vaccine trialsNonreplicating vectors in HIV vaccines.Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectorsFirst-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individualsRecombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili studyProtection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.Genetic immunization in the lung induces potent local and systemic immune responses.Induction of immunity to human immunodeficiency virus type-1 by vaccination.Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccinesRegulation of SIV antigen-specific CD4+ T cellular immunity via autophagosome-mediated MHC II molecule-targeting antigen presentation in mice.Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccineA trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challengePreexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigenRelevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.Neutralizing antibodies to HIV-1 induced by immunization.Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 studyAntibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDSVaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21.The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaquesProtection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cellsRecombinant vaccines and the development of new vaccine strategies.Novel HIV vaccine strategies: overview and perspective.Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.
P2860
Q27024614-F09B3464-A44D-4AD1-AFA3-1FCFC4172C81Q27319783-F1F13684-A425-4A2B-899E-22516FE953ACQ27321063-9ACA6E0A-C92F-4502-9B9D-D24B98DAB9A7Q28731894-D91BEEBB-B33D-4A31-A0E7-1D7426E8ABDDQ30410411-36F26499-1DFF-4844-97D3-4B1335268EB0Q30411492-C1E23C58-A4F1-4A0C-A37A-25F0AD2B13C5Q30420558-2AE5C69A-0C49-4401-A722-83A1EED5B7B3Q30424366-29639F50-558A-4E1D-9D25-E3B36D4DDDB9Q33693891-EDBF1E40-A5DA-43B0-A129-11D2F5079306Q33999615-15FC44A1-117C-42BA-AF12-4BE61F8FEEF1Q34057708-167EEE07-088D-4C7C-9228-4100DBDE36E8Q34209026-A279AFC3-7823-48D5-9700-ED75C108925BQ34218500-C4E08BBA-4287-461F-9049-464C0FD22147Q34240204-2AA93482-1BF7-4DF5-8E0F-3D02935AC5D6Q34358402-D1337863-1903-4D5F-8850-4C406661ACEDQ34438559-2F8ED0E1-0CD9-4D1A-A2A8-BC860CB98D1AQ34540645-0AF0B86E-8ED6-449A-B389-9C475EA9D7DCQ34774808-B6888D7E-2415-4000-8B18-850D994EC92CQ35132375-B4FA8793-7BB7-49F7-AF1B-B7A4569BAE88Q35173777-F0BB9A85-1098-4AEA-A6A8-DF72D29B687DQ35344875-F1BD4DA0-CED8-45E8-A57E-D2500F36113AQ35640645-59E47122-E944-4AAC-963B-EEF427BF09D1Q36024470-85DFB2F2-F888-43B5-A412-FA92AE9DAE83Q36154059-51568BA2-AB95-47AD-A65F-A7C34C38ADF3Q36369321-0F597349-73AA-4D68-BEEC-A54E120B614FQ36474557-CD08BF7D-C24E-4579-A5AA-89AE196CE75BQ36487887-CE1D16ED-A22F-4DB0-A15B-F7B3B4B649CDQ36495581-F607D113-065F-43D2-89E1-A3042D094552Q36495587-A03045D3-8A6D-4EA1-BD5B-2B0EEB3100A9Q36555158-8E1E8C00-7BDB-451C-A93F-B30B2702727AQ36603515-62EBAA41-7B5F-40B3-97D0-3B4445DECA48Q36621905-C16ADF03-3805-47E1-8C55-1C6B85AF238CQ36667821-2614ECEF-5073-4BC3-A946-9EADD869CCB6Q36768279-B9BFEA75-7375-4B65-A6AD-BBAAE2FDB684Q36903830-6CD127F0-F363-4A21-9ED6-650B3ECF4461Q37181386-FBEF11CF-0B75-4D1B-9A9B-115A7205E014Q37218080-50147B39-47C5-4A1F-8409-A927DA95CB83Q37370940-624ECD36-DE0C-4D08-AD39-5CB6C5B02A52Q37668399-62D8B30E-8C80-4552-BC99-12C72A06E96EQ37932525-B8B9EE4E-A8B0-467D-B38A-2717ADAF3995
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Novel adenovirus vector-based vaccines for HIV-1.
@ast
Novel adenovirus vector-based vaccines for HIV-1.
@en
Novel adenovirus vector-based vaccines for HIV-1.
@nl
type
label
Novel adenovirus vector-based vaccines for HIV-1.
@ast
Novel adenovirus vector-based vaccines for HIV-1.
@en
Novel adenovirus vector-based vaccines for HIV-1.
@nl
prefLabel
Novel adenovirus vector-based vaccines for HIV-1.
@ast
Novel adenovirus vector-based vaccines for HIV-1.
@en
Novel adenovirus vector-based vaccines for HIV-1.
@nl
P2860
P1476
Novel adenovirus vector-based vaccines for HIV-1.
@en
P2860
P304
P356
10.1097/COH.0B013E32833CFE4C
P577
2010-09-01T00:00:00Z